APPLICATION OF GENETICALLY ENGINEERED TUMOR-SPECIFIC TH1 CELLS TO ADOPTIVE TUMOR IMMUNOTHERAPY

スポンサーリンク

概要

• 論文の詳細を見る

• CD4+ Th cells, in particular IFN-γ-producing Th1 cells, play a critical role in the activation and maintenance of CD8+ Tc1 cells that are essential for tumor eradication. Recent identification of MHC class II binding peptides derived from tumor antigens theoretically made possible to tumor-specific CD4+ T cells in addition to CD8+ T cells induced by MHC class I binding tumor antigen peptides. However, the generation of tumor-specific T cells is still a practically challenging and time-consuming procedure. This fact makes difficult the application of tumor-specific T cells to adoptive immunotherapy of cancer patients. Recently, novel methods have been developed to prepare tumor-specific T cells from nonspecifically activated T cells by gene transfer. Specifically, two types of genes were shown to be successful when they were introduced into nonspecific-T cells to generate genetically engineered tumor-specific T cells. One is the TCR α and β chain genes obtained from tumor-specific T cells, and the other is the chimeric immunoglobulin-T cell receptor (cIgTCR) gene which contains a single chain variable fragment from antitumor monoclonal antibody. In this review, we overviewed these methods briefly, and showed our recent results generating genetically engineered tumor-specific Th1 cells successfully by both these methods. In both mouse and human systems, non-specifically activated Th1 cells transduced with TCR genes specific for tumor antigen-derived peptide showed potent antitumor activity against tumor cells when they recognized tumor antigen peptide presented on MHC molecules. On the other hand, Th1 cells transduced with a cIgTCR gene specific for carcinoembryonic antigen, CEA, were shown to be reactive with cell surface CEA in an MHC independent manner. Taken together, these results strongly suggest that it is possible to prepare tumor-specific human Th1 cells by gene transfer technique that is applicable to adoptive tumor immunotherapy for cancer patients.

著者

• Chamoto Kenji

  Division Of Immunoregulation Institute For Genetic Medicine Hokkaido University

• Nishimura Takashi

  Division Of Arrhythmia And Electrophysiology Department Of Cardiovascular Medicine National Cerebral

• Ikeda Hiroaki

  Division Of Immunoregulation Institute For Genetic Medicine Hokkaido University

• Tsuji Takemasa

  Division of Immunoregulation, Institute for Genetic Medicine Hokkaido University

• Gyobu Hiroshi

  Division of Immunoregulation, Institute for Genetic Medicine Hokkaido University

関連論文

• CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific T_h2-cell migration into lung
• Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer
• Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer
• 7 Need of prompt introduction of implantable LVAS into Japanese therapeutic strategy for severe heart failure(Symposium 8 (SY-08) (M) New Strategies for Management of Severe Heart Failure with New Devices and Surgery,Special Program,The 72nd Annual Scient
• An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen
• 1α,25-Dihydroxyvitamin D3 downmodulates the functional differentiation of Th1 cytokine-conditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lymphocyte generation
• STAT6-mediated signaling in Th2-dependent allergic asthma : critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation
• The critical role of type-1 innate and acquired immunity in tumor immunotherapy
• 3-Methylcholanthrene-induced transforming growth factor-β-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy
• Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy
• The interface between innate and acpuired immunity: glycolipid antigen presentation by CD1 d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes
• Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells
• Unexpected role of TNF-α in graft versus host reaction (GVHR) : donor-derived TNF-α suppresses GVHR via inhibition of IFN-γ-dependent donor type-1 immunity
• Differential regulation of VLA-2 expression on T_h1 and T_2 cells : a novel marker for the classification of T_h subsets
• An efficient method to prepare T cell receptor gene-transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell-therapy
• APPLICATION OF GENETICALLY ENGINEERED TUMOR-SPECIFIC TH1 CELLS TO ADOPTIVE TUMOR IMMUNOTHERAPY
• Blocking of IL-6 signaling pathway prevents CD4^+ T cell-mediated colitis in a T_h17-independent manner
• Triple-site pacing : a new supported therapy approach for bridge to recovery with a left ventricular assist system in a patient with idiopathic dilated cardiomyopathy
• Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells
• AsialoGM1^+CD8^+ central memory-type T cells in unimmunized mice as novel immunomodulator of IFN-γ-dependent type 1 immunity
• Interleukin-12-responding asialoGM1^+CD8^+ central memory-type T cells as precursor cells for interferon-γ-producing killer T cells
• Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
• A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific T_h1 cells
• A T_h17-polarized cell population that has infiltrated the lung requires cells that convert to IFN-γ production in order to induce airway hyperresponsiveness
• Potential of Selected Strains of Lactic Acid Bacteria to Induce a Th1 Immune Profile
• New pre-clotting method for fibrin glue in a non-sealed graft used in an LVAD : the KYO method
• Successful treatment of cerebral hemorrhage using computed tomography angiography in a patient with left-ventricular-assist device
• Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

もっと見る 閉じる

スポンサーリンク